Effects of Curcumin-Piperine Supplementation in Fibromyalgia
Key facts
- Phase
- Phase 2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ain Shams University
- Trial code
- NCT07753018
- Record updated
- 11 August 2026
- Original description
The goal of this clinical trail is to evaluate the effectiveness and safety of curcumin-piperine supplementation in patients with fibromyalgia over 3 months compared to placebo.Read full original descriptionShow less
Evaluation of the Effect of Curcumin and Piperine Supplementation on Clinical Outcome in Fibromyalgia Patients.
The goal of this clinical trail is to evaluate the effectiveness and safety of curcumin-piperine supplementation in patients with fibromyalgia over 3 months compared to placebo.
Participants will:
Be randomly assigned to receive either curcumin and piperine supplements or a placebo.
Attend scheduled clinic visits for clinical assessments and blood sample collection.
Complete study questionnaires before and after treatment time frame.
The primary question the study aim to answer is:
Does Curcumin-piperine supplementation reduce pain intensity by Visual Analog Scale (VAS), compared with placebo?
The secondary questions this study aims to answer are:
Does supplementation improve fibromyalgia disease impact and quality of life? Does supplementation improve inflammatory biomarkers and oxidative stress? Does supplementation improve insulin resistance? Is curcumin and piperine supplementation safe and well tolerated?
Inclusion: Adult women aged ≥18 years; Patients with confirmed diagnosis of fibromyalgia, according to 2022 ACR Fibromyalgia criteria.
Exclusion: Patients receiving other anti-inflammatory medications; Patients receiving anticoagulant medications (e.g., clopidogrel); Patients with chronic inflammatory or autoimmune diseases other than FM; Patients allergic to curcumin or piperine; Severe hepatic or renal impairment; Diabetic patients (HbA1c ≥ 6.5); Pregnancy or lactation; Participation in another clinical trial.